None
Quote | Trevi Therapeutics Inc. (NYSE:TRVI)
Last: | $ |
---|---|
Change Percent: | -3.42% |
Open: | $5.36 |
Close: | $5.0413 |
High: | $5.38 |
Low: | $4.82 |
Volume: | 4,689 |
Last Trade Date Time: | 02/12/2020 04:42:08 pm |
News | Trevi Therapeutics Inc. (NYSE:TRVI)
2024-05-11 13:56:10 ET Trevi Therapeutics, Inc. (TRVI) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Jennifer Good - President and Chief Executive Officer Lisa Delfini - Chief Financial Officer David Clark - Chief Medical Officer ...
Trevi Therapeutics to Participate in Upcoming Conferences PR Newswire NEW HAVEN, Conn. , May 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™...
Message Board Posts | Trevi Therapeutics Inc. (NYSE:TRVI)
Subject | By | Source | When |
---|---|---|---|
TRVI....................................https://stockcharts.com/h-sc/ui?s=TRVI&p | glenn1919 | investorshub | 04/22/2023 12:14:27 PM |
Uptick Network: $TRVI Trevi Therapeutics, Inc. News ~ Progress & 2022 Success of Clinical Studies fo | Uptick Network | investorshangout | 02/07/2023 4:50:35 PM |
Uptick Network: $TRVI updates! Trevi Therapeutics, Inc. Discusses Progress and 2022 Success of Clini | Uptick Network | investorshangout | 01/31/2023 10:58:24 AM |
Uptick Network: $TRVI News out! Trevi Therapeutics, Inc. ~ Progress and 2022 Success of Clinical Stu | Uptick Network | investorshangout | 01/30/2023 12:10:25 PM |
Uptick Network: $TRVI Trevi Therapeutics, Inc. Discusses Progress and 2022 Success of Clinical Studi | Uptick Network | investorshangout | 01/25/2023 5:41:17 PM |
News, Short Squeeze, Breakout and More Instantly...
Trevi Therapeutics Inc. Company Name:
TRVI Stock Symbol:
NYSE Market:
Trevi Therapeutics Inc. Website:
Trevi Therapeutics to Participate in Upcoming Conferences PR Newswire NEW HAVEN, Conn. , May 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™...
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates PR Newswire Reaffirms guidance for the Phase 2a RIVER trial in refractory chronic cough and Human Abuse Potential (HAP) Study with topline data for each expected in the second half of...
Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024 PR Newswire Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn. , May 1, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc...